By Miguel Regueiro, MD, with Marcus A. Banks
This month’s report focuses on two different ongoing conundrums in the inflammatory bowel disease space, one that primarily pertains to treatment of adults and the other to treatment of children.
When treating adults with Crohn’s disease with advanced therapies—biologics or small molecules—I think